REYON Pharmaceutical Co., Ltd. (KRX: 102460)
South Korea flag South Korea · Delayed Price · Currency is KRW
12,820
-490 (-3.68%)
Dec 19, 2024, 9:00 AM KST

REYON Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
149,842151,071154,039142,801130,034131,558
Upgrade
Other Revenue
-0-0---0-
Upgrade
Revenue
149,842151,071154,039142,801130,034131,558
Upgrade
Revenue Growth (YoY)
-0.49%-1.93%7.87%9.82%-1.16%6.97%
Upgrade
Cost of Revenue
76,70773,34773,47564,34858,28258,058
Upgrade
Gross Profit
73,13577,72480,56478,45371,75273,500
Upgrade
Selling, General & Admin
63,04164,30666,28663,15161,00860,361
Upgrade
Research & Development
3,1438,3756,7059,7256,5843,724
Upgrade
Other Operating Expenses
1,061981.05942.46958.94884.68788.67
Upgrade
Operating Expenses
69,08675,95176,11676,90970,09866,878
Upgrade
Operating Income
4,0481,7734,4481,5451,6546,622
Upgrade
Interest Expense
-184.54-195.53-122.2-111.19-178.01-116.33
Upgrade
Interest & Investment Income
410.98802.87994.76527.96992.161,744
Upgrade
Earnings From Equity Investments
-1,478-960.18-1,9681,684-475.29-358.51
Upgrade
Currency Exchange Gain (Loss)
129.12124.67-91.5512.434.2114.27
Upgrade
Other Non Operating Income (Expenses)
1,1764,938-945.79514.97430.31-273.94
Upgrade
EBT Excluding Unusual Items
4,1026,4832,3154,1732,4277,632
Upgrade
Gain (Loss) on Sale of Investments
-3,184-3,1834,2621,1251,57397.92
Upgrade
Gain (Loss) on Sale of Assets
691.56732.32317.22547.04367.42-5.16
Upgrade
Other Unusual Items
-273.27-----1,167
Upgrade
Pretax Income
1,3364,0326,8945,8454,3686,557
Upgrade
Income Tax Expense
720.28448.59-539.77307.51523.261,613
Upgrade
Earnings From Continuing Operations
615.83,5837,4345,5373,8444,944
Upgrade
Minority Interest in Earnings
-----1.87
Upgrade
Net Income
615.83,5837,4345,5373,8444,946
Upgrade
Preferred Dividends & Other Adjustments
--75125--
Upgrade
Net Income to Common
615.83,5837,3595,4123,8444,946
Upgrade
Net Income Growth
-92.70%-51.80%34.25%44.03%-22.28%268.33%
Upgrade
Shares Outstanding (Basic)
181818181717
Upgrade
Shares Outstanding (Diluted)
181818181717
Upgrade
Shares Change (YoY)
-1.91%0.46%3.03%4.05%1.01%-0.80%
Upgrade
EPS (Basic)
33.57195.38414.51305.44225.75293.40
Upgrade
EPS (Diluted)
33.20195.00407.18305.00225.75293.40
Upgrade
EPS Growth
-92.72%-52.11%33.50%35.10%-23.06%271.31%
Upgrade
Free Cash Flow
-19,613-20,225-54,404-105,293-47,708-63,113
Upgrade
Free Cash Flow Per Share
-1069.34-1102.71-2979.96-5942.30-2801.53-3743.71
Upgrade
Dividend Per Share
150.000150.000150.000250.000200.000343.137
Upgrade
Dividend Growth
0%0%-40.00%25.00%-41.71%-30.00%
Upgrade
Gross Margin
48.81%51.45%52.30%54.94%55.18%55.87%
Upgrade
Operating Margin
2.70%1.17%2.89%1.08%1.27%5.03%
Upgrade
Profit Margin
0.41%2.37%4.78%3.79%2.96%3.76%
Upgrade
Free Cash Flow Margin
-13.09%-13.39%-35.32%-73.73%-36.69%-47.97%
Upgrade
EBITDA
8,1696,5558,9816,2106,21910,710
Upgrade
EBITDA Margin
5.45%4.34%5.83%4.35%4.78%8.14%
Upgrade
D&A For EBITDA
4,1204,7824,5344,6664,5654,088
Upgrade
EBIT
4,0481,7734,4481,5451,6546,622
Upgrade
EBIT Margin
2.70%1.17%2.89%1.08%1.27%5.03%
Upgrade
Effective Tax Rate
53.91%11.13%-5.26%11.98%24.60%
Upgrade
Advertising Expenses
-76.91106.0956.01152.9265.77
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.